David V Gold et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(24), 7380-7387 (2007-12-21)
The anti-MUC1 monoclonal antibody (MAb), PAM4, has a high specificity for pancreatic adenocarcinoma compared with other cancers, normal tissues, or pancreatitis. In order to assess its role in early pancreatic cancer development, we examined the expression of the PAM4-reactive MUC1